Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. - Archive ouverte HAL Access content directly
Journal Articles Oncotarget Year : 2012

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.

(1, 2) , (1, 3, 4) , (1, 2) , (1)
1
2
3
4

Abstract

Patients with normal karyotype represent the single largest cytogenetic group of acute myeloid leukemia (AML), with highly heterogeneous clinical and molecular characteristics. In this study, we sought to determine new prognostic biomarkers in cytogenetically normal (CN)-AML patients. A gene expression (GE)-based risk score was built, summing up the prognostic value of 22 genes whose expression is associated with a bad prognosis in a training cohort of 163 patients. GE-based risk score allowed identifying a high-risk group of patients (53.4%) in two independent cohorts of CN-AML patients. GE-based risk score and EVI1 gene expression remained independent prognostic factors using multivariate Cox analyses. Combining GE-based risk score with EVI1 gene expression allowed the identification of three clinically different groups of patients in two independent cohorts of CN-AML patients. Thus, GE-based risk score is powerful to predict clinical outcome for CN-AML patients and may provide potential therapeutic advances.
Fichier principal
Vignette du fichier
Devlpmt_of_gene_expression-based.pdf (497.09 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-00726665 , version 1 (04-09-2012)

Identifiers

  • HAL Id : inserm-00726665 , version 1
  • PUBMED : 22910040

Cite

Elias Bou Samra, Bernard Klein, Thérèse Commes, Jérôme Moreaux. Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.. Oncotarget, 2012, 3 (8), pp.824-32. ⟨inserm-00726665⟩
134 View
469 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More